Caelyx
Caelyx
Overview
Caelyx is a liposomal formulation of doxorubicin, an anthracycline chemotherapeutic agent used in oncology. As a nanomedicine, it is designed to alter the pharmacokinetic and tissue-distribution properties of doxorubicin relative to the free drug, with the goal of improving delivery to tumors while reducing some systemic toxicities. In recent biomedical literature, liposomal doxorubicin is frequently discussed in the context of drug delivery barriers, tumor microenvironment constraints, and combination regimens intended to enhance antitumor activity.
Biologically, Caelyx is relevant because doxorubicin remains a widely used cytotoxic agent across multiple malignancies, including breast, head and neck, colorectal, prostate, and hematologic cancers. Research involving Caelyx often focuses on how liposomal encapsulation interacts with vascular permeability, interstitial fluid pressure, stromal barriers, and adjunctive technologies such as ultrasound, microbubbles, magnetic systems, and radiotherapy to improve intratumoral accumulation. It is also studied in relation to doxorubicin-associated toxicities, especially cardiotoxicity, and to mechanisms of resistance involving apoptosis, redox homeostasis, and the tumor microenvironment.
Recent Publications Focus
Below is a summary of the newest research publications targeting Caelyx (sorted by publication date).
Recent publications have predominantly focused on optimizing doxorubicin delivery systems and exploring rational combination strategies to enhance therapeutic efficacy while mitigating systemic toxicity. A clinical phase II study of liposomal doxorubicin combined with nab-paclitaxel in unresectable locally advanced or recurrent/metastatic adenoid cystic carcinoma of the head and neck achieved an objective response rate of 90.3%, with a median progression-free survival of 25.7 months and 1-year overall survival of 90%, while maintaining a manageable safety profile with grade 3 treatment-related adverse events in only 25.8% of patients [42285940]. This represents one of the highest reported tumor response rates for this aggressive malignancy and demonstrates the clinical viability of liposomal formulations in combination regimens.
Beyond clinical translation, numerous preclinical studies have engineered advanced nanocarrier platforms to improve doxorubicin delivery. Aptamer-functionalized liposomes modified with AS1411 exhibited uniform size distribution and superior tumor-targeting specificity in breast cancer models [42339546], while fibroblast activation protein-α-responsive lipid nanoparticles with size-transformable properties significantly improved stromal penetration and drug accumulation in fibrotic hepatocellular carcinoma, reducing interstitial barriers that typically limit efficacy [42328782]. Alternative nanoplatforms utilizing magnetic particles, carbon dots, and graphene oxide have demonstrated enhanced intracellular delivery and controlled release kinetics, with some systems achieving IC50 reductions in multidrug-resistant tumor cells up to 87.7-fold compared to free doxorubicin [42007566, 41534500].
Combination therapy strategies have yielded particularly promising results. Integration of doxorubicin with photothermal therapy in anaplastic thyroid carcinoma enhanced cellular uptake, increased reactive oxygen species generation, exacerbated DNA damage, and importantly reduced doxorubicin-induced cardiotoxicity while promoting immunogenic cell death [42243048]. An inhalable platform utilizing liquid nitrogen-treated tumor cells as both drug carriers and immunostimulators demonstrated superior tumor suppression and significantly prolonged survival in pulmonary metastasis models through sustained local chemotherapy delivery coupled with robust dendritic cell activation and CD8+ T cell recruitment [41947504]. Additionally, photodynamic-chemotherapy conjugates combining natural chlorins with doxorubicin enabled controlled release and dual-modality cytotoxicity, with evidence of doxorubicin nuclear accumulation following linker cleavage [41793941].
Emerging strategies addressing the tumor microenvironment and drug resistance mechanisms have also incorporated doxorubicin. Smart magnetic nanozymes have been rationally designed to target redox homeostasis regulators and reverse multidrug resistance through multimodal activation via vibrational magnetic fields and near-infrared irradiation [42007566], while superparamagnetic iron oxide nanoclusters simultaneously delivered doxorubicin and DNase to degrade neutrophil extracellular traps, preventing metastasis while enhancing chemotherapeutic efficacy [41529527]. Studies comparing free doxorubicin with liposomal formulations have highlighted the importance of drug formulation in influencing blood-brain barrier penetration and delivery efficiency when combined with microbubble-mediated focused ultrasound technologies [41748412], establishing the continued relevance of optimizing liposomal carriers for challenging biological barriers.